A phase II study of sacituzumab tirumotecan combined with tagitanlimab as first-line treatment for patients with KRAS-mutant advanced non-small cell lung cancer (ESMO Asia 2026) - Oct 1, 2026 - Abstract #707TiP; Pres time: Dec 4, 2026; 05:15 PM - 06:15 PM; Location: Poster area (Exhibition); No abstract available
Clinical • Metastases • P2 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • KRAS
|
|
Fangqi Li; Wei Zhang; Hua Zhong; Baohui Han
|